GET DAILY SIGNALSWhy Is Odyssey Therapeutics (ODTX) Stock Down 0.42% Today?
Key Takeaways
- ODTX shares slipped about 0.42% in Monday morning trading, easing to roughly $19.15 from a prior close of $19.23.
- The modest decline follows a volatile stretch around the company's third-quarter 2026 earnings, reported on November 4.
- No single company-specific headline drove the move; the pullback largely reflects post-earnings consolidation and light profit-taking.
- A wave of recent analyst initiations — including Buy ratings from H.C. Wainwright, UBS, and Raymond James — has kept the clinical-stage biotech in the spotlight.
- Broader biotechnology sentiment remains mixed as investors weigh rate-sensitive, pre-revenue names.
- Traders are watching upcoming OD-001 clinical updates and progress toward the Phase 2b program.
- For additional detail on this name, explore Price Targets, Earnings, and Forecast pages for ODTX.
- For automated, data-driven trading ideas across the market, explore Trending AI Robots.
Opening Summary
ODTX — Odyssey Therapeutics, Inc. — is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for autoimmune and inflammatory diseases, led by its RIPK2 inhibitor OD-001 in ulcerative colitis. In Monday's session, shares traded down roughly 0.42% to about $19.15, compared with Friday's closing level of $19.23. The decline was modest and did not appear tied to a single corporate announcement, pointing instead to a period of consolidation following several days of outsized moves around the company's recent earnings report.
Post-Earnings Consolidation and Profit-Taking
The most immediate backdrop for ODTX is its third-quarter 2026 results, released November 4. The company reported a wider net loss — up roughly 50% year over year to about $53.1 million — while disclosing roughly $387 million in cash, cash equivalents, and marketable securities. The stock swung sharply around the release, rallying 8% the prior session before giving back ground as investors absorbed the expanded quarterly loss. Monday's fractional dip is consistent with a market still digesting those results rather than reacting to fresh news.
A Flurry of Analyst Initiations
Offsetting the near-term selling pressure has been a notable cluster of bullish analyst coverage. In recent weeks, several firms have initiated or reiterated positive ratings on ODTX, including Buy-equivalent initiations from H.C. Wainwright, UBS, and Raymond James, with price targets generally well above the current share price. The Street's enthusiasm is concentrated on OD-001, where Phase 2a induction data showed 27% clinical remission and 61% clinical response in ulcerative colitis patients. While this coverage supports the medium-term narrative, it has not prevented shorter-term traders from locking in gains after the stock's recent volatility.
Broader Biotech Sentiment
The pullback also arrives against a mixed backdrop for the biotechnology sector. Pre-revenue, development-stage companies such as ODTX are especially sensitive to shifts in risk appetite and interest-rate expectations, which can influence the valuation of far-off cash flows. With no major macro catalyst driving the tape Monday, the sector's small-cap names traded in a largely directionless fashion, and ODTX followed that subdued tone.
Market Context and Trading Activity
Trading in ODTX during the early session was comparatively light, a contrast to the elevated volume that accompanied the November 4 earnings release, when turnover surged well above the stock's typical daily average. The shares remain within a recent range roughly between the high teens and low twenties, still trading below the late-October and early-November peaks near the $22 level. The stock's 52-week range spans roughly $15 to $29, leaving the current price near the middle of that band and without an obvious technical break to either side in Monday's action.
What Comes Next for ODTX
Looking ahead, investors will focus on execution across the clinical pipeline. Key catalysts include additional analyses from the OD-001 Phase 2a program and the planned Phase 2b monotherapy study, as well as the OD-001 plus vedolizumab combination trial, with topline induction readouts targeted for the second half of 2027. Progress on OD-002, a first-in-class oral SLC15A4 inhibitor that has completed IND-enabling studies, is another area of interest. Risks remain substantial: as a pre-revenue company, ODTX faces clinical, regulatory, and financing uncertainties, and trial timelines can shift. The strong "Buy" consensus from analysts stands alongside a history of widening quarterly losses, leaving the stock sensitive to any update on data timing or cash runway.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols they trade. Only the strongest performers are featured in this section. Explore Trending AI Robots to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ODTX turns negative, indicating new downward trend
ODTX saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator turned negative. In 5 of the 5 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ODTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
ODTX broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for ODTX just turned positive on October 20, 2026. Looking at past instances where ODTX's MACD turned positive, the stock continued to rise in 1 of 2 cases over the following month. The odds of a continued upward trend are 50%.
Following a +1.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where ODTX advanced for three days, in 19 of 23 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ODTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.194) is normal, around the industry mean (3.498). P/E Ratio (-5.755) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. ODTX's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ODTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement